羧基麦芽糖铁及其在缺铁性贫血中的应用进展

发布时间：2018-04-08 12:03

本文选题：羧基麦芽糖铁　切入点：静脉铁剂　出处：《中国新药杂志》2017年09期

【摘要】：缺铁性贫血(iron deficiency anemia,IDA)是目前全球最常见的营养素缺乏疾病之一,其治疗药物主要以铁剂为主,口服铁剂应用较早、价廉方便,但效果不理想。静脉铁剂的出现弥补了口服铁剂吸收差、起效慢和不良反应大的不足。近年来新型静脉铁剂不断出现,羧基麦芽糖铁能够满足临床大剂量快速给药的需求,市场前景广阔,是优点最突出的新型静脉铁剂。文章概括了羧基麦芽糖铁的基本理化信息、合成方法、代谢机制、临床研究、国际销售以及国内注册等情况,对羧基麦芽糖铁在国内的研究开发和推广提供了参考。
[Abstract]:Iron deficiency anemia IDA is one of the most common nutrition deficiency diseases in the world at present. Its therapeutic drugs are mainly iron and iron, oral iron is used earlier, cheap and convenient, but the effect is not satisfactory.The presence of intravenous iron makes up for the poor absorption, slow onset and large adverse reactions of oral iron.In recent years, a new type of intravenous iron has been developed. Carboxymaltose iron can meet the needs of high dose and fast delivery in clinic. It has a broad market prospect and is the most outstanding new type of intravenous iron.In this paper, the basic physical and chemical information, synthetic method, metabolic mechanism, clinical research, international sales and domestic registration of carboxymaltose iron are summarized, which provides a reference for the research and development of carboxymaltose iron in China.
【作者单位】：中国药科大学理学院;江苏神龙药业有限公司;
【基金】：江苏省“创新团队计划”项目(2013-043) 江苏省“六大高峰人才”项目(2013-SWYY-009)
【分类号】：R259

【相似文献】